当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-09-08 , DOI: 10.1056/nejmoa1709937 Scott J. Antonia 1 , Augusto Villegas 1 , Davey Daniel 1 , David Vicente 1 , Shuji Murakami 1 , Rina Hui 1 , Takashi Yokoi 1 , Alberto Chiappori 1 , Ki H. Lee 1 , Maike de Wit 1 , Byoung C. Cho 1 , Maryam Bourhaba 1 , Xavier Quantin 1 , Takaaki Tokito 1 , Tarek Mekhail 1 , David Planchard 1 , Young-Chul Kim 1 , Christos S. Karapetis 1 , Sandrine Hiret 1 , Gyula Ostoros 1 , Kaoru Kubota 1 , Jhanelle E. Gray 1 , Luis Paz-Ares 1 , Javier de Castro Carpeño 1 , Catherine Wadsworth 1 , Giovanni Melillo 1 , Haiyi Jiang 1 , Yifan Huang 1 , Phillip A. Dennis 1 , Mustafa Özgüroğlu 1
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-09-08 , DOI: 10.1056/nejmoa1709937 Scott J. Antonia 1 , Augusto Villegas 1 , Davey Daniel 1 , David Vicente 1 , Shuji Murakami 1 , Rina Hui 1 , Takashi Yokoi 1 , Alberto Chiappori 1 , Ki H. Lee 1 , Maike de Wit 1 , Byoung C. Cho 1 , Maryam Bourhaba 1 , Xavier Quantin 1 , Takaaki Tokito 1 , Tarek Mekhail 1 , David Planchard 1 , Young-Chul Kim 1 , Christos S. Karapetis 1 , Sandrine Hiret 1 , Gyula Ostoros 1 , Kaoru Kubota 1 , Jhanelle E. Gray 1 , Luis Paz-Ares 1 , Javier de Castro Carpeño 1 , Catherine Wadsworth 1 , Giovanni Melillo 1 , Haiyi Jiang 1 , Yifan Huang 1 , Phillip A. Dennis 1 , Mustafa Özgüroğlu 1
Affiliation
|
Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461.)
中文翻译：
III期非小细胞肺癌放化疗后的Durvalumab
与安慰剂相比，durvalumab的无进展生存期明显更长。次要终点也偏爱durvalumab，两组之间的安全性相似。（由阿斯利康资助； PACIFIC ClinicalTrials.gov编号，NCT02125461。）
更新日期：2017-11-16
中文翻译：
III期非小细胞肺癌放化疗后的Durvalumab
与安慰剂相比，durvalumab的无进展生存期明显更长。次要终点也偏爱durvalumab，两组之间的安全性相似。（由阿斯利康资助； PACIFIC ClinicalTrials.gov编号，NCT02125461。）
京公网安备 11010802027423号